Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Minnesota: - Fairview Clinics and Surgery Center Maple Grove — Maple Grove, Minnesota
- Hennepin County Medical Center — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Monticello Cancer Center — Monticello, Minnesota
- Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Minnesota: - Minnesota Oncology Hematology, P.A — Fridley, Minnesota
- Allina Health Cancer Institute — Minneapolis, Minnesota
Phase 3 Recruiting Industry
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease p…
Sponsor: Replimune, Inc.
NCT ID: NCT06264180
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Sites in Minnesota: - Allina Health Cancer Institute - Minneapolis — Minneapolis, Minnesota
Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Sponsor: IDEAYA Biosciences
NCT ID: NCT07015190
Sites in Minnesota: - Mayo Clinic - PPDS — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with im…
Sponsor: Replimune, Inc.
NCT ID: NCT06581406
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents,…
Sponsor: Immunocore Ltd
NCT ID: NCT05549297
Sites in Minnesota: - University of Minnesota Medical Center — Minneapolis, Minnesota
- Mayo Clinic Minnesota — Rochester, Minnesota
Phase 3 Recruiting Industry
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …
Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Minnesota: - Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Saint Mary's - Detroit Lakes Clinic — Detroit Lakes, Minnesota
Phase 2 Recruiting NIH
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in Minnesota: - Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Abbott-Northwestern Hospital — Minneapolis, Minnesota
- North Memorial Medical Health Center — Robbinsdale, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Minnesota: - Research Site 121 — Saint Paul, Minnesota
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Minnesota: - Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination w…
Sponsor: Perspective Therapeutics
NCT ID: NCT05655312
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota: - Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Minnesota: - Minnesota Oncology and Hematology PA — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Minnesota: - Mayo Clinic in Minnesota — Rochester, Minnesota
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Minnesota: - HealthPartners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Methodist Hospital Inpatient Pharmacy — Saint Louis Park, Minnesota
- HealthPartners Cancer Center at regions Hospital — Saint Paul, Minnesota
- Regions Hospital Pharmacy — Saint Paul, Minnesota
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Minnesota: - Regions Hospital Cancer Care Center — Saint Paul, Minnesota
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Minnesota: - Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota